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Abstract  1 
Purpose: The Macular Degeneration Quality of Life (MacDQoL) instrument is a 2 
validated condition-specific measure of quality of life in patients with macular 3 
degeneration. This paper presents the first mapping algorithm to predict EQ-5D from 4 
responses to the MacDQoL instrument.  5 
Methods: Responses to the MacDQoL and EQ-5D-3L instruments from 482 patients 6 
were collected from the IVAN multicentre trial of two alternative drug treatments for 7 
neovascular age-related macular degeneration. Regression specifications were 8 
estimated using OLS, censored least absolute deviation, Tobit and two-part models. 9 
Their predictive performance was assessed using mean squared error. An internal 10 
validation sample based on a random selection of 25% of patients was used to 11 
assess the performance of the model estimated on the remaining 75% of patients.  12 
Results: A two-part model had the best predictive performance on the full sample. 13 
The covariates of this model include responses and weighted impact scores for all 23 14 
condition specific domains of the MacDQoL, and responses to a general MacDQoL 15 
quality of life question. The selected models were successful at predicting means and 16 
standard deviations of target populations, but prediction is weaker at the upper and 17 
lower extremes of the EQ-5D-3L distribution.   18 
Conclusion: The mapping algorithms provide a means of predicting EQ-5D-3L index 19 
scores from MacDQoL scores, and could facilitate cost-effectiveness analyses when 20 
the latter but not the former are available to researchers. Further validation of the 21 
performance of the algorithms using external data would provide a means of 22 
establishing the robustness of the algorithms.  23 
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Introduction  24 
There is growing interest from health economists and quality-of-life researchers in 25 
understanding the relationship between condition-specific and generic measures of 26 
patient outcome, especially where the former but not the latter are collected within 27 
clinical trials and other study contexts [1-3]. Condition-specific measures of health-28 
related quality of life (HRQoL) may offer greater sensitivity than generic measures [4]. 29 
However, for health care commissioners, generic measures are useful in providing 30 
comparable information on effectiveness and cost-effectiveness across different 31 
interventions and patient groups.  32 
There is evidence that validity, sensitivity and responsiveness of generic measures 33 
differs between diseases [5]. Recent studies have suggested that the responsiveness 34 
of generic HRQoL measures in visual disorders may be limited [2; 5] although the 35 
evidence base in this area is small. Our paper examines the relationship between 36 
generic and condition-specific measures of HRQoL in macular degeneration. Age-37 
related macular degeneration is a progressive chronic eye disease. It is a leading 38 
cause of irreversible blindness and visual disability, accounting for approximately 39 
50% of all vision impairments or blind registrations in developed countries [6]. 40 
Prevalence is expected to increase significantly in the developing world with 41 
demographic change leading to aging populations [7]. In the UK, 39,700 new cases 42 
of neovascular macular degeneration are estimated to occur each year, with an 43 
estimated prevalence of 263,000 cases nationally [8]. Estimated prevalence at 44 
different age groupings in the UK ranges from 0.1% of men and women aged 50-54 45 
to 24.7% of men aged over 90 and 25.6% of women [8]. Given the large number of 46 
patients with the condition, it is important to explore the HRQoL improvements 47 
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associated with various treatments for the condition and assess how incremental 48 
cost-effectiveness compares with interventions for other conditions in order to assess 49 
where and how limited healthcare resources should be best deployed.  50 
The MacDQoL (Macular Degeneration Quality of Life) [9] is a macular degeneration-51 
specific outcome measure. The MacDQoL is considered acceptable to patients and 52 
is related to several vision measures [10]. Its test-retest reliability has been confirmed 53 
[11], as have its metric properties in UK, French, German, Italian and American 54 
populations [12].  Translations or adaptations are available in 15 languages [9]. 55 
There is currently no mechanism to estimate EQ-5D values from responses to the 56 
MacDQoL instrument. This is a potential limitation of the instrument as health state 57 
preference values are required to inform cost-effectiveness analyses in technology 58 
appraisals and drug reimbursement decisions. While direct elicitation studies require 59 
recruitment of a new sample of patients or citizens answering cognitively challenging 60 
questions, mapping studies can be conducted on existing datasets. The objective of 61 
our paper was to use trial data on patients with age-related macular degeneration to 62 
produce a set of coefficients that can be used to reliably transform patients’ 63 
responses on the MacDQoL questionnaire to EQ-5D-3L index scores. It is 64 
understood to the first example of MacDQoL being mapped onto a generic utility 65 
instrument.  This paper presents mapping algorithms that predict generic EQ-5D-3L 66 
index scores from the MacDQoL. 67 
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Methods 68 
The data were derived from the IVAN trial [13; 14],a UK factorial randomised 69 
controlled trial which assessed ranibizumab versus bevacizumab for the treatment of 70 
macular degeneration. Participants aged 50 and above had active but previously 71 
untreated neovascular age-related macular degeneration in the study eye, and were 72 
randomised to receive ranibizumab or bevacizumab, and either discontinuous 73 
treatment or continuous monthly injections for two years. IVAN participants 74 
completed both MacDQoL and EQ-5D-3L at three time points.  75 
HRQoL instruments 76 
The MacDQoL consists of two general overview questions and 23 specific questions 77 
or domains. The two general items (DQOL-I and DQOL-II) are scored individually and 78 
measure generic present quality of life (DQOL-I), and macular degeneration-specific 79 
quality of life (DQOL-II) [10]. Each of the 23 specific domains contains an ‘impact’ 80 
question1 and an ‘importance’ question2. The use of an importance-weighted impact 81 
allows for an overall weighted impact of each item to be calculated as the product of 82 
an impact rating and an importance rating, with a range from -9 (maximum negative 83 
impact of macular degeneration) to +3 (maximum positive impact of macular 84 
degeneration).  The average weighted impact score is calculated from the sum of 85 
weighted ratings specific domains divided by the number of applicable domains, and 86 
also has a range from -9 to +3. The use of both individualised impact and importance 87 
responses reflects how MacDQoL was designed to capture the quality of life impacts 88 
 
1
 Impact response categories are answered in response to questions such as ‘If I did not have macular degeneration, 
friendships and social life would be’. Typical categories are ‘very much better' [scoring -3], ‘much better' [scoring -2], ‘a little 
better' [scoring -1], ‘the same' [scoring 0], and ‘worse’ [scoring +1].  
2
 Importance response categories are answered in response to questions such as ‘My friendships and social life are..’ with 
response categories ‘very important' [scoring 3], ‘important' [scoring 2], ‘somewhat important' [scoring 1], ‘not at all important’ 
[scoring 0].   
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of macular degeneration, rather than simply measuring only the functional impact of 89 
the condition of visual performance. A more extended discussion of the instrument is 90 
presented in [10] and in the online supplementary material.  91 
EQ-5D-3L is a standardised, generic measure of health status that provides a 92 
descriptive profile of health states, and a single index value for health status [15]. It is 93 
the preferred utility instrument of the National Institute for Health and Care 94 
Excellence (NICE) [16]. The index value is anchored on a maximum value of 1 for 95 
perfect health, 0 to represent death, and negative values that reflect states worse 96 
than death. It contains 5 dimensions: mobility; self-care; usual activities; pain and 97 
discomfort; and anxiety and depression. The three level version (EQ-5D-3L) 98 
measures these dimensions by three categories, corresponding to no problems, 99 
some problems, and extreme problems.  100 
Data The 610 adults participating in IVAN self-completed large print EQ-5D-3L 101 
questionnaires in UK English (with assistance from research nurses where 102 
necessary) at baseline, at 3, 12 and 24 months, at study exit and after serious 103 
adverse events. EQ-5D-3L responses were valued using the UK time trade-off tariff 104 
[17].  105 
MacDQoL was administered in English by telephone at 3, 12 and 24 months during 106 
the IVAN trial. Data from all time points were eligible for inclusion in the analysis.  107 
Four domains of the MacDQoL instrument allowed people to respond ‘Not applicable’ 108 
(or similar), instead of answering the impact/importance questions: work, personal 109 
relationships, family life, and holidays. These values were recoded to zero (to 110 
indicate no impact on quality of life) so as to be retained for analysis in for some of 111 
the estimated models; this is described in more detail in the online appendix 112 
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(Supplementary Material 1). Observations with missing data on any other MacDQoL 113 
or any of the five EQ-5D-3L index questions were excluded from the analysis.  114 
The MacDQoL instrument was due to be administered 14 days after EQ-5D-3L to 115 
reduce patient burden but on 1,008 occasions (88% of all instances for which paired 116 
data on the date of EQ-5D-3L and MacDQoL are available), it was completed more 117 
than 14 days after the EQ-5D, with a mean difference of 41 days later than protocol. 118 
Only observations where the MacDQoL was completed no more than 90 days after 119 
EQ-5D-3L completion, and no more than 1 day before EQ-5D-3L was due to be 120 
administered, were used in our mapping analysis in order to ensure consistency 121 
between the EQ-5D-3L and the MacDQoL instruments. Sensitivity analyses varying 122 
this cut-off, and further details of this issue, are reported in the online appendix 123 
(Supplementary Material 1). After excluding patients who did not complete both the 124 
EQ-5D-3L and MacDQoL within the specified timeframe, and the 20 observations 125 
with missing data on one or more EQ-5D-3L or MacDQoL questions, the regression 126 
analyses were estimated with up to 817 observations from 462 patients (70% of 127 
those randomised) out of 858 MacDQoL responses (95% of all completed MacDQoL 128 
questionnaires included in the analysis).  129 
Statistical methods  130 
The objective of the analysis was to estimate mean EQ-5D-3L values from participant 131 
responses to the MacDQoL instrument. To assess the degree of overlap between the 132 
two instruments, we first estimated Spearman’s rho (rank correlation coefficients) 133 
showing the correlations between EQ-5D-3L and DQOL-I, DQOL-II and the 134 
MacDQoL using the –spearman- Stata command.   135 
Regression models using different specifications and different estimators were 136 
applied to the data in order to identify models that predicted EQ-5D-3L successfully, 137 
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as determined by mean squared error (MSE) and mean absolute error (MAE).  There 138 
is no clear guidance as to which of MSE and MAE is preferable [18]. MSE was used 139 
as the primary measure here because it penalises deviations from the mean more 140 
heavily than does the MAE. Four estimators that have been used in previous 141 
mapping studies [3] were applied and their predictive performance compared: 142 
ordinary least squares (OLS); Tobit; centred least absolute deviations (CLAD); and 143 
two-part models.  144 
The starting point for this analysis was the estimation of linear OLS models. Linear 145 
models are widely used in mapping studies [3], and offer a useful basis for 146 
comparison with more complex models. They also retain the possibility of being 147 
predictively successful in their own right.  OLS predictions of EQ-5D-3L values >1 148 
were recoded to 1. A criticism of OLS models is that they do not reflect the natural 149 
‘ceiling’ of EQ-5D-3L values at 1, and require this ex-post recoding adjustment. 150 
Alternative estimators that account directly for the upper limit on EQ-5D-3L were 151 
therefore also assessed.  152 
Tobit models [19] allow for continuous dependent variables that have constrained 153 
ranges, and therefore can allow for the censoring of EQ-5D-3L at 1. The model 154 
estimates, using maximum likelihood, a continuous distribution for values of EQ-5D-155 
3L index scores below the ceiling value of 1, while placing a positive (discrete) 156 
probability value on the censored outcome of EQ-5D=1. The rationale for applying 157 
Tobit is to allow the estimator to reflect the natural ceiling of EQ-5D-3L at perfect 158 
health (when EQ-5D-3L=1) rather than to model the censoring to which Tobit models 159 
are usually applied [19]. Pullenayegum et al [20] note that Tobit (and CLAD – see 160 
below) models may be biased, when the intention is to perform economic evaluation, 161 
if it is assumed that ‘true’ utility extends beyond 1. However, any potential bias of an 162 
estimator is of secondary concern in the context of this study, where we are aiming to 163 
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accurately predict mean EQ-5D-3L index scores, rather than to produce, for example, 164 
unbiased estimates of covariates that are believed to be causally associated with 165 
quality of life.    166 
We also estimated the CLAD models [21] using the –clad- command in Stata [22]. 167 
CLAD models, which minimise absolute deviations from the median, are similar to 168 
Tobit models in their capacity to account for the upper limit in EQ-5D-3L as a 169 
dependent variable in regressions, but differ from Tobit models in being consistent 170 
even if error terms are not normal and having standard errors that are robust to 171 
heteroskedasticity.  172 
The final set of estimators comprised two-part models. These models account for the 173 
upper limit of EQ-5D-3L by separately modelling individuals at the upper limit of EQ-174 
5D, and modelling those individuals below this limit. Unlike Tobit, CLAD and OLS 175 
models, the two-part model uses two different estimators to produce a single 176 
estimate.  Specifically, two-part models estimate in the binary first ‘part’ a logistic 177 
regression to predict the probability of having an EQ-5D-3L score equal to exactly 1 178 
(Probability(Utility = 1)), and in the second part use an OLS model to predict utility (U) 179 
for those individuals with less than perfect health (i.e. EQ-5D-3L scores <1). The 180 
second part of the two-part model therefore regresses the EQ-5D score on the same 181 
or a closely related set of covariates as used in the first part on those patients with 182 
less than perfect health. For the OLS part of the two-part model model, predictions of 183 
EQ-5D-3L of greater than 1 were again recoded to 1. Predictions are produced by 184 
combining the predictions of the first-part logit model with those of the second-part 185 
OLS model by weighting the OLS prediction by the probability of having imperfect 186 
health using the following formula: 187 
Predicted Utility = Probability(Utility=1) + (1 – Probability(Utility=1))*U 188 
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Seemingly unrelated regression (SUR), implemented with the –suest- command in 189 
Stata, was used to adjust the standard errors of the two-part model to allow for 190 
correlation between the error terms of the two parts of the model.  191 
For each estimator, we explored the performance of a number of different model 192 
specifications with using different scores or responses from MacDQoL. We explored 193 
some models in which each MacDQoL domain was coded using one ordinal variable 194 
measuring response level. We also evaluated whether weighted impact scores (the 195 
product of impact and importance) improved EQ-5D-3L predictions. However, the 196 
latter two specifications treat the MacDQoL responses as though they were 197 
continuous, implicitly assuming that the levels between response levels are evenly 198 
spaced. We therefore also explored the impact of using dummy variables for different 199 
levels of the ordinal response variables, which recognises that the variable has a 200 
categorical nature. Further specifications considered the effect on predictive 201 
accuracy of recoding or excluding questions with an ‘N/A’ response. 202 
MacDQoL impact variables had limited numbers of responses in some of the most 203 
extreme categories, which meant that econometric models including dummy 204 
variables for all response levels dropped variables. To address this issue, responses 205 
were recoded for models using dummy variables so that the most extreme responses 206 
were collapsed into adjacent categories: the ‘Very much better’ and ‘Much better’ 207 
categories were merged, as were the ‘Worse’ and ‘The same categories’. Only 14 208 
MacDQoL responses (1.6%) indicated that macular degeneration improved quality of 209 
life in any domain. Estimating models without merging these categories therefore 210 
tended to produce collinearity and could not be estimated (see online supplementary 211 
material). It may be worth investigating this issue in the future if a much larger 212 
dataset becomes available for analysis. The recoded domain responses used in the 213 
analysis therefore had three levels.  214 
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We excluded from consideration model specifications that did not have convergent 215 
likelihood, which excluded large parts of the sample (because of low levels of data on 216 
one variable) and/or which dropped variables because of perfect collinearity. 217 
Coefficients with p>0.05 and/or with counterintuitive signs were retained in model 218 
specifications given that the primary objective of the estimated models was to 219 
maximise prediction accuracy.  220 
Twenty two different model specifications were evaluated for each of the four 221 
different estimators, producing up to 88 MSE values. A list of combinations of model 222 
specification and estimator is presented in Tables 4 and 5 of the online appendix. 223 
The appropriateness of model specification was determined by reference to 224 
predictive accuracy. The predictive accuracy of the chosen specification were also 225 
assessed by examining Q-Q plots of actual versus predicted EQ-5D index scores, 226 
scatter plots of actual versus predicted scores, and simple distributional comparisons 227 
(see online supplementary material).  228 
All models were estimated using Stata version 13.1 (Statacorp: College Station, 229 
Texas) using clustering to adjust standard errors to allow for repeated observations 230 
made on individual patients.  231 
Validation 232 
Ideally, the prediction accuracy of a mapping algorithm should be tested on an 233 
external dataset to assess whether the model is ‘over-fitted’ to noise in the data 234 
rather than the underlying relationship, and to evaluate how the model will perform in 235 
other datasets. External data were not available in this case, so an internal validation 236 
sample was used [1]. This was conducted by using the (pseudo)-random number 237 
generating function in Stata to select a 25% ‘validation’ sample (n=115) leaving an 238 
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‘estimation’ sample with the remaining 75% of data (n=367). This percentage split is 239 
typical of that used in other studies [23].  240 
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Results 241 
Summary statistics 242 
Participants in the IVAN trial had a mean age of 77.7 years, of whom 60% were 243 
female. Participants needed a best corrected distance of visual acuity of at least 25 244 
letters on the Early Treatment Diabetic Retinopathy Study chart to be eligible for 245 
inclusion, and the mean at baseline was 61.4 letters [13]. Some 14% of individuals 246 
randomised had angina, 19% dyspnoea and less than 10% had experienced one or 247 
both of myocardial infarction or stroke; 64% were current or past smokers [13]. Table 248 
1 presents descriptive statistics for the key variables used in the analysis for this 249 
paper for the 482 patients with no missing data on EQ-5D-3L and MacDQoL domains 250 
used in regression analysis. Further information on the demographic characteristics 251 
of participants in the IVAN trial is available in [13].    252 
Table 1 Summary statistics of HRQoL instruments 253 
 254 
 Full sample (N=860 
observations from 482 
patients) 
Estimation sample 
(N=655 observations 
from 367 patients) 
Validation sample 
(N=205 observations 
from 115 patients) 
EQ-5D: mean (SD)a 0.8417 (0.1960) 
Min: -0.181 Max: 1 
0.8459 (0.1912) 
Min: -0.181 Max: 1 
0.8282 (0.2108) 
Min: -0.077  Max: 1 
MacDQoL weighted 
impact: mean (SD) 
-1.8801 (1.7902) 
Min: -9 Max: 0.1363 
-1.9670 (1.8352) 
Min:-9 Max:0.1363 
-1.6005 (1.61003) 
Min: -7.318 Max: 0 
DQOL-I: mean (SD) 
1.3934 (0.9947) 
Min: -3  Max: 3 
1.4167 (1.0115) 
Min: -3 Max: 3 
1.3186 (0.9371) 
Min:-1 Max: 3 
DQOL-II: mean (SD) 
-1.4639 (1.0393) 
Min: -3 Max: 1 
-1.4984 (1.0113) 
Min: -3 Max: 1 
-1.3529 (1.1198) 
Min: -3 Max: 1 
a – SD: Standard deviation. 255 
 256 
Some 21% of responses to the DQOL-I question (macular degeneration-specific 257 
quality of life) indicated no negative impact of macular degeneration on HRQoL. EQ-258 
5D-3L and DQOL-I, DQOL-II and the MacDQoL average weighted impact measure 259 
were highly correlated under Spearman’s rho, and the null of independence was 260 
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strongly rejected in all cases (p<0.01). Lower EQ-5D-3L scores were correlated with 261 
lower MacDQoL estimates of quality of life. There was a small cluster of observations 262 
with low EQ-5D-3L scores: 0.58% of observations were below 0, and 3.95% were 263 
below 0.5.  264 
Mapping MacDQoL onto EQ-5D-3L  265 
The best-performing model differed depending on whether predictive accuracy was 266 
assessed using the estimation sample or the validation sample (Supplementary 267 
material 1, Tables 4 and 5).  268 
The model having the lowest MSE in the estimation sample (Model 4 – see 269 
Supplementary material for numbering) was a two-part model that included dummy 270 
variables for all 23 MacDQoL domains and continuous interactions of impact and 271 
importance for all of these domains in the first (logit) part of the model, while the 272 
second (OLS) part of the model included the same set of covariates, plus the generic 273 
quality of life measure DQOL-I (treated as a continuous variable).  274 
The model with the lowest MSE in the validation sample (Model 5) was an OLS 275 
model estimated on all 23 MacDQoL domains treated as dummy variables, and 276 
continuous interactions of impact and importance for all of these domains. This is the 277 
same set of covariates as the first part of the two-part model selected in the 278 
estimation sample.   279 
When these models were estimated on the full sample of 817 observations and 280 
predictions generated, the two-part Model 4 had a better predictive performance than 281 
the OLS Model 5. Generally, it is more appropriate to select models based on their 282 
performance in the validation sample to avoid over-fitting and typically the model that 283 
performs best in the validation sample also performs best on the full sample. 284 
However, in this case, results differ markedly because the validation sample has 285 
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lower mean EQ-5D-3L scores and prediction errors are especially bad for such 286 
patients. In the validation sample, 9.28% of observations had EQ-5D-3L <0.6, 287 
compared with 6.42% in the estimation sample. Differences in the distribution of EQ-288 
5D-3L between the two samples may have affected the choice of model and 289 
estimator.  290 
Table 2 Summary comparison of observed and predicted EQ-5D-3L on full, estimation 291 
and validation samples  292 
Variable Na Mean 
Standard 
deviation 
Minimum Maximum MSEd MAEd 
Observed data        
Observed EQ-5D-3L – full 
regression sample 
817 0.8441 0.1937 -0.181 1   
Observed EQ-5D-3L –
estimation sample 
623 0.8488 0.1886 -0.181 1   
Observed EQ-5D-3L –
validation sample 
194 0.8290 0.2091 -0.077 1   
Predictions – two-part Model 4b 
Predicted EQ-5D-3L from 
two-part model 
817 0.8481 0.0844 0.4037 1 0.0293 0.1269 
Predicted EQ-5D-3L from 
two-part model – 
estimation sample 
623 0.8523 0.0944 0.2089 1 0.0256 0.1178 
Predicted EQ-5D-3L from 
two-part – validation 
sample  
194 0.8668 0.0924 0.4511 1 0.0500 0.1631 
Predictions - OLS Model 5c 
Predicted EQ-5D-3L from 
OLS model – full sample  
817 0.8436 0.0785 0.4837 1 0.0310 0.1329 
Predicted EQ-5D-3L from 
OLS model – estimation 
sample  
623 0.8480 0.0880 0.3317 1 0.0273 0.1245 
Predicted EQ-5D-3L from 
OLS model – validation 
sample  
194 0.8619 0.0884 0.4235 1 0.0494 0.1642 
a – Number of observations: Of the 482 patients included in any regression analysis, 20 were excluded from the 293 
OLS and two-part models shown here because of missing data in EQ-5D-3L scores and MacDQoL domains 294 
variables used in regressions. This reduced the number of available observations by 43 from 860 to 817 for the 295 
largest regression samples.  296 
b - Specification of first part of Model 4: A logistic regression to predict EQ-5D=1 where covariates comprised all 297 
23 MacDQoL domain responses as dummy variables, and all 23 weighted impact variable values as continuous 298 
variables. Specification of second part of Model 4: An OLS regression of EQ-5D-3L values for those patients with 299 
EQ-5D index scores<1, using the same explanatory variables the first part, plus the DQOL-I variable as a 300 
continuous variable.  301 
c - Specification of Model 5: An OLS regression of EQ-5D-3L values in which explanatory variables comprised all 302 
23 MacDQoL domains treated as dummy variables, and continuous interactions of impact and importance for all 303 
of these domains.  304 
d - Values shown in bold are the lowest in their respective samples of those estimated and displayed in the table. 305 
 306 
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We therefore took the conservative approach of presenting both models: i.e. those 307 
informed by predictive accuracy of models in both the estimation sample (Model 4) 308 
and the validation sample (Model 5). Variance-covariance matrices are available as 309 
online appendix (Supplementary Material 2) and can be used to estimate standard 310 
errors around predicted values when the mapping algorithm is applied to other 311 
samples. 312 
  313 
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Table 3 Coefficients to predict EQ-5D-3L from MacDQoL estimated using the full 314 
sample (n=817) 315 
Variable Two-part Model 4 OLS Model 5 
Logit coefficients 
(SE) 
OLS coefficients 
(SE) 
Coefficients (SE) 
Household tasksa  A little better -0.0035 (0.3125) -0.0353 (0.0281) -0.0200 (0.0239) 
Much better or very 
much better 
0.2789 (0.4947) -0.0223 (0.0419) -0.0092 (0.0366) 
Personal affairsa A little better -0.7794 (0.3088) 0.0148 (0.0285) -0.0333 (0.026) 
Much better or very 
much better 
-1.0097 (0.5231) 0.0469 (0.0427) -0.0107 (0.0413) 
Shoppinga A little better 0.4939 (0.2855) -0.0113 (0.0253) 0.0256 (0.023) 
Much better or very 
much better 
0.2746 (0.4576) -0.0544 (0.0383) -0.0022 (0.0337) 
Worka A little better -0.2048 (0.7607) 0.0168 (0.0844) -0.0003 (0.0583) 
Much better or very 
much better 
-1.5117 (1.3659) 0.0189 (0.0948) -0.0610 (0.08) 
Relationshipsa A little better 0.2794 (0.5866) -0.0462 (0.0664) -0.0283 (0.0495) 
Much better or very 
much better 
0.6153 (1.0143) -0.0321 (0.1257) 0.0128 (0.0902) 
Family lifea A little better -0.5902 (0.4357) -0.0655 (0.0374) -0.063 (0.0323) 
Much better or very 
much better 
-1.0378 (0.7979) -0.1384 (0.0726) -0.1320 (0.0685) 
Friendshipsa A little better -0.137 (0.346) -0.0014 (0.0279) -0.0078 (0.0265) 
Much better or very 
much better 
0.6822 (0.6614) -0.044 (0.0495) 0.0105 (0.0481) 
Physical 
appearancea 
A little better -0.4769 (0.4034) 0.0245 (0.0328) -0.0045 (0.0291) 
Much better or very 
much better 
-1.0209 (0.8434) 0.0102 (0.0678) -0.0381 (0.0566) 
Physical activitya A little more -0.2113 (0.3348) 0.0543 (0.0316) 0.0159 (0.0274) 
Much more or very 
much more 
-0.9505 (0.555) 0.0316 (0.0541) -0.0291 (0.0488) 
Out and abouta A little better -0.7453 (0.3237) -0.0325 (0.0313) -0.0567 (0.0282) 
Much better or very 
much better 
-1.5539 (0.5259) 0.0177 (0.0463) -0.0819 (0.0484) 
Holidaysa A little better 0.1084 (0.2988) 0.015 (0.0281) 0.0186 (0.0231) 
Much better or very 
much better 
-1.035 (0.4759) 0 (0.0401) -0.0198 (0.0339) 
Leisure and 
hobbiesa 
A little more 0.0764 (0.2922) -0.021 (0.0295) -0.0029 (0.025) 
Much more or very 
much more 
0.1379 (0.4243) -0.0296 (0.0402) -0.0176 (0.0347) 
Self-confidencea A little better 0.5343 (0.3112) -0.0033 (0.0271) 0.0171 (0.0235) 
Much better or very 
much better 
1.2402 (0.5675) -0.0053 (0.0477) 0.0538 (0.0404) 
Motivationa A little better 0.1446 (0.3171) 0.0535 (0.0263) 0.0363 (0.0239) 
Much better or very 
much better 
0.4464 (0.5721) 0.0581 (0.049) 0.0514 (0.0438) 
A little better -0.1992 (0.4257) 0.0740 (0.0389) 0.0454 (0.0366) 
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Reaction of 
othersa 
Much better or very 
much better 
0.32 (0.7181) 0.0354 (0.0776) 0.061 (0.073) 
Feelings about the 
futurea 
A little better 0.1088 (0.2805) -0.0314 (0.0246) -0.0098 (0.0235) 
Much better or very 
much better 
0.0033 (0.3993) 0.004 (0.038) 0.0063 (0.0323) 
Financial 
situationa 
A little better 0.0984 (0.7161) -0.0346 (0.0441) -0.0164 (0.047) 
Much better or very 
much better 
-0.207 (1.6711) -0.1145 (0.0996) -0.1115 (0.1009) 
Independencea A little better 0.3108 (0.3318) 0.0263 (0.0281) 0.0275 (0.0274) 
Much better or very 
much better 
0.3307 (0.5383) 0.0746 (0.0523) 0.0517 (0.0461) 
Doing things for 
othersa 
A little better -0.2579 (0.2987) 0.0457 (0.029) 0.0024 (0.0254) 
Much better or very 
much better 
-0.2808 (0.5) -0.0079 (0.0495) -0.0312 (0.0419) 
Experiencing 
mishaps or losing 
thingsa 
A little better 0.234 (0.3211) -0.0607 (0.0299) -0.0171 (0.0277) 
Much better or very 
much better 
0.9399 (0.6205) -0.0512 (0.0684) 0.0115 (0.0594) 
Enjoyment of 
mealsa 
A little more -0.2301 (0.3928) 0.0181 (0.0254) 0.0067 (0.0292) 
Much more or very 
much more 
1.0081 (0.647) 0.0185 (0.0606) 0.0656 (0.0576) 
Time taken to do 
thingsa 
A little less -0.3971 (0.244) 0.0033 (0.0298) -0.0264 (0.0223) 
Much less or very 
much less 
-0.1084 (0.4568) 0.0401 (0.0419) 0.0091 (0.0359) 
Enjoyment of 
naturea 
A little more -0.0565 (0.3128) 0.0027 (0.0251) 0.0001 (0.0231) 
Much more or very 
much more 
-1.0278 (0.4949) 0.0114 (0.0313) -0.038 (0.0358) 
Impact/importance 
interaction 
Household tasks -0.0378 (0.0816) -0.0102 (0.0071) -0.0102 (0.0063) 
Personal affairs -0.1396 (0.0753) 0.0024 (0.0066) -0.0022 (0.0062) 
Shopping 0.056 (0.0679) -0.0049 (0.0058) 0.0016 (0.005) 
Work -0.3265 (0.228) 0.0084 (0.0221) -0.0116 (0.0161) 
Relationships -0.0583 (0.1677) -0.0129 (0.0204) -0.0106 (0.014) 
Family life -0.1342 (0.1198) -0.0196 (0.0122) -0.0146 (0.0103) 
Friendships 0.0432 (0.0971) -0.0116 (0.008) -0.0028 (0.0076) 
Physical 
appearance 
-0.0846 (0.1306) 0.0022 (0.0107) -0.0015 (0.0089) 
Physical activities -0.0975 (0.0946) -0.0006 (0.0096) -0.0045 (0.0086) 
Out and about -0.2568 (0.0768) 0.0074 (0.008) -0.0105 (0.0079) 
Holiday -0.1742 (0.0903) -0.0038 (0.0088) -0.0098 (0.007) 
Leisure 0.0469 (0.0628) -0.002 (0.0055) -0.0006 (0.0048) 
Self-confidence 0.2509 (0.0887) -0.0016 (0.0075) 0.0107 (0.0067) 
Motivation -0.0764 (0.088) 0.0153 (0.0079) 0.0043 (0.0073) 
Reaction of others 0.2273 (0.1279) 0.0221 (0.017) 0.0312 (0.0159) 
Feelings about the 
future 
-0.0212 (0.0582) -0.0032 (0.0058) -0.0036 (0.0046) 
Financial situation 0.1248 (0.2599) -0.0151 (0.015) -0.0084 (0.0158) 
Independence 0.1857 (0.0734) 0.0111 (0.0073) 0.0162 (0.0068) 
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a: All 23 items in the MacDQoL instrument begin with ‘If I did not have macular degeneration>’ The respondent is 316 
then asked to consider the impact of the condition on the activities described above and rate it on a five-point 317 
scale (worse, same, a little better, much better, or very much better). The two extreme categories have been 318 
combined with the second most extreme. The reference response to these questions is ‘Same or worse’ – 319 
meaning that the variables should be interpreted against a patient response that the presence of macular 320 
degeneration has no impact on that specific domain or their actions in that domain would be worse without 321 
macular degeneration. 322 
b:R2 values are those associated with the respective regressions used to generate these coefficients – pseudo R2 323 
in the case of the logit regression and adjusted R2 in the case of the OLS regressions.   324 
For the OLS model, EQ-5D-3L values can be calculated from the coefficients in this table by taking the constant 325 
term (0.8781) and adding the coefficients for the relevant item responses (e.g. adding -0.02 if the patient would 326 
find household tasks a little better if they did not have macular degeneration), then, for each domain, adding on 327 
the product of the coefficient for the impact/importance interaction (e.g.-0.0378 for household tasks), that patient’s 328 
impact score on that domain (e.g. 2 if they would find household tasks a little better) and their importance score 329 
(e.g. 3 if household tasks are very important to them). For both OLS and two-part models, the impact scores used 330 
to calculate weighted impact should be Worse=0, The same=1, A little better=2, Much better=3, Very much 331 
better=4, and for Importance: 0=Not at all important, 1= Somewhat important, 2=Important, 3=Very important.  332 
EQ-5D-3L values can be calculated in a similar way for the two-part model. The procedure for the OLS 333 
component of the two-part model (U) is as described for the OLS model but using coefficients from the second 334 
column of data in the table above. The log odds of having perfect health (utility = 1) can be calculated by taking 335 
the constant term (0.2991) and adding on the coefficients for the relevant impact item responses and the product 336 
of the coefficient for weighted impact scores, that patient’s impact score and their importance score. Log-odds 337 
should then be converted to probabilities by taking the exponent of the log odds to calculate the odds of a utility of 338 
1 and dividing the odds by 1+odds to give Probability(Utility=1). Predicted utility can then be calculated as: 339 
Predicted Utility = Probability(Utility=1) + (1 – Probability(Utility=1))*U 340 
 341 
The purpose of the regressions is to predict EQ-5D-3L index scores rather than 342 
estimate the magnitude and sign of coefficients, but the following example shows 343 
how these coefficients may be interpreted. The ‘Personal affairs’ question asks the 344 
respondent to state ‘If I did not have [macular degeneration], I could handle my 345 
personal affairsQ’. Using the recoded variables deployed in the analysis, the 346 
coefficient of the OLS regression on the ‘Better or very much better’ dummy of the 347 
‘Personal Affairs’ question is -0.0107, which can be interpreted as suggesting that 348 
Do for others -0.1099 (0.0792) -0.0013 (0.0075) -0.0072 (0.0066) 
Mishaps 0.0835 (0.0957) -0.0055 (0.0116) 0.0008 (0.0101) 
Enjoyment of meals 0.1699 (0.0946) 0.0106 (0.0119) 0.0163 (0.011) 
Time taken to do 
things 
0.0215 (0.0775) 0.0028 (0.0072) 0.0022 (0.0065) 
Enjoyment of 
nature 
-0.0596 (0.0746) 0.0036 (0.0052) -0.0005 (0.0055) 
DQOL-I   0.0358 (0.0105)  
Constant  0.2991 (0.1705) 0.6701 (0.0264) 0.8781 (0.0146) 
Pseudo R2 b 
Adjusted R2 b 
 0.1363  
0.0450 
 
0.0940 
MSE (full sample)  0.0293 0.0310 
MAE (full sample)  0.1269 0.1329 
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patients who could manage their personal affairs much better or very much better 349 
would have approximately 1% lower EQ-5D-3L scores than patients for whom 350 
macular degeneration had no impact on management of their personal affairs. The 351 
coefficients cannot be given a causal interpretation, and in any event there is no clear 352 
pattern amongst the coefficients that indicate which domains of MacDQoL might 353 
have a particular influence on EQ-5D index scores. In the OLS models, coefficients 354 
including ‘family life’ impacts have p-values <0.05, and likewise the ‘personal affairs’ 355 
impact domain in the logit model. Several coefficients (e.g. shopping on the two-part 356 
logit model) have counterintuitive signs, suggesting that EQ-5D-3L scores would be 357 
improved if macular degeneration had a larger impact on that domain. However, all 358 
variables were kept in the model to avoid reducing prediction accuracy by omitting 359 
parts of the source instrument.  360 
Prediction errors were high at the extremes of the EQ-5D-3L distribution, particularly 361 
the lower end, while errors were smaller near mean EQ-5D-3L: MSE is <0.1 for 362 
values within ±0.15 of mean EQ-5D-3L (Figure 1). This suggests that the accuracy of 363 
prediction, as measured by MSE, is smallest when predicting mean EQ-5D-3L 364 
compared to other quantiles of EQ-5D-3L. This suggests that both algorithms are 365 
better suited to prediction of mean EQ-5D-3L from MacDQoL than for values far from 366 
mean EQ-5D-3L index scores.   367 
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Fig. 1 MSE at different levels of EQ-5D-3L – full sample, two-part  Model 4 368 
 369 
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Discussion 370 
This paper has presented the methods and results of a mapping algorithm that 371 
generates EQ-5D-3L values from responses to the condition-specific MacDQoL 372 
instrument. The mapping algorithm can be used to estimate EQ-5D-3L index values 373 
in circumstances where only MacDQoL data is available – this circumstance may 374 
arise in study designs where the latter but not the former has been collected by 375 
researchers. Although MacDQoL is not widely used at present, this may change with 376 
increasing research on eye disease. Estimated models are successful at predicting 377 
the mean EQ-5D-3L for this specific sample, but may be less successful for 378 
predicting individuals’ utility (particularly for those with low or very high utility). We 379 
found that the predictive performance of the studied models is weaker for patients 380 
with EQ-5D-3L values <0.6 than for values≥0.6. A similar trend has been 381 
encountered in other literature concerned with eye disease and HRQoL [24]. For 382 
cost-effectiveness analysis, accurate prediction of sample means may be more 383 
important than the scores of individuals at particular parts of the utility distribution 384 
[25].  385 
As this is the first study mapping between these instruments, it was not possible to 386 
compare the predictive performance against other published studies, and it is 387 
important to test the algorithm presented here on other datasets when they become 388 
available. A review of mapping studies in other areas [26] found MAE estimates to 389 
range between 0.0011 to 0.19, which encompasses the MAEs found in this study for 390 
the selected models (0.1269 for the two-part model and 0.1329 for the OLS model). 391 
The only other study mapping predicting EQ-5D-3L for patients with macular 392 
degeneration  identified in a recent systematic review [3] reported a root mean 393 
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square error of 0.2163 for its recommended model when mapping from the National 394 
Eye Institute Vision Function Questionnaire [27]. The square of this term is 0.0468, 395 
which is somewhat larger than the MSEs for preferred models in the different 396 
samples (Models 4 and 5) of 0.0293 and 0.0310, although comparisons are affected 397 
by the different samples and instruments involved.   398 
Our best performing models included some coefficients that were non-significant 399 
and/or had counterintuitive signs. This has also been observed in previous studies, 400 
including those with much larger samples [28]. Such counterintuitive signs could 401 
cause the mapping algorithm to predict a reduction in EQ-5D when the patient’s 402 
MacDQoL profile has improved and could reflect collinearity within our sample or 403 
genuine opposition between domains. We suggest that it is appropriate to include the 404 
whole of the source instrument for completeness, and because omitting inconsistent 405 
or non-significant coefficients can reduce prediction accuracy [28]. Selecting models 406 
based on information criteria may have given a more parsimonious model, but are 407 
not appropriate for selecting mapping models, where prediction accuracy is the main 408 
concern [1; 29; 30].  409 
Participants in IVAN had mean baseline EQ-5D-3L index scores of 0.85, which is 410 
higher than estimates of UK age-adjusted mean population norms [31], potentially 411 
because of the trial inclusion criteria and the requirement for monthly visits [32]. This 412 
is a limitation of the study if the relationship between the two instruments varies with 413 
patients’ general health. If slope coefficients were to change when estimated on a 414 
population in worse health, this would affect the level of QALYs estimated, but not 415 
necessarily affect estimates of incremental QALYs or incremental cost-effectiveness. 416 
Further validation of the mapping models on an external dataset is required to assess 417 
prediction accuracy in other populations.  418 
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The choice of estimator differed depending on whether model selection was based 419 
on MSE in the validation sample or MSE in the estimation sample. This could be 420 
explained by the greater proportion of individuals with low EQ-5D-3L scores in the 421 
validation sample. An external validation dataset would provide a more robust test of 422 
the model’s overall predictive accuracy, and may offer evidence regarding the 423 
applicability of the algorithm to other types of patient population.   424 
The sample size of this study is a limitation. A larger sample size would improve the 425 
precision of estimates, and may address the differences between validation and 426 
estimation samples as well as the small number of instances of counter-intuitive 427 
signs of particular variables in the preferred model specification. Larger sample sizes 428 
may also support the application of other potentially relevant approaches such as 429 
response mapping [33]. The number of observations available used in this analysis 430 
(817) is below the median (1,167) and mean (6,069) number of observations in a 431 
recent review [3] of mapping studies.  432 
MacDQoL, like other ‘DQoL’ instruments, asks patients to rate the importance of 433 
each domain, as well as rating the impact of their condition. We found that the 434 
product of importance and impact affected EQ-5D utility over and above the effect of 435 
impact scores. An unexplored issue is whether it is reasonable to map from a 436 
disease-specific instrument that uses these patient-reported measures of importance 437 
to a generic instrument (EQ-5D) that uses valuations of preferences between health 438 
states provided by members of the general public. We note that NICE guidance for 439 
technology appraisal [16] recommends the use of a generic instrument valued using 440 
public (not patient) preferences, but does not specify the characteristics that ought to 441 
be possessed by disease-specific instruments from which EQ-5D index values are 442 
obtained via mapping algorithms.  443 
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Conclusion 444 
Our paper presents the first set of algorithms to map from MacDQoL to health state 445 
values, which will facilitate cost-effectiveness studies in this area. The models are 446 
reasonably simple, in that any dataset with complete responses to MacDQoL can be 447 
used to predict EQ-5D, with no additional data required. The methods described are 448 
also likely to be applicable to similar analyses in other disease areas.  The models 449 
presented in this paper can be used to estimate mean EQ-5D-3L values in other 450 
samples. However, our models have been evaluated only on patients with 451 
neovascular age-related macular degeneration with MacDQoL average weighted 452 
impact scores between -9 and 0.14, with a median value of -1.36, and future work is 453 
required to assess whether our models would perform as well in other patient groups.  454 
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